Treatment - Page 28 of 471 Posts on Medivizor

Evaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.

Posted by Medivizor on Jan 23, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of combining proton radiotherapy (PRT) plus carbon-ion radiotherapy (CIRT) with chemotherapy (CT) given at the same time in patients with limited-stage (LS) small cell lung cancer (SCLC). The data showed that PRT plus CIRT with CT given at the same time was effective with manageable side...

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

Posted by Medivizor on Jan 23, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of radiotherapy (RT) for the treatment of patients with indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that RT was highly effective with manageable side effects in these patients. Some background Non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells...

How useful is bortezomib maintenance after allogeneic stem cell transplant in young or high-risk patients with multiple myeloma?

Posted by Medivizor on Jan 23, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the use of bortezomib (BTZ; Velcade) maintenance after allogeneic hematopoietic cell transplant (alloHCT) for improving relapse and chronic graft versus host disease (cGVHD) in patients with multiple myeloma (MM) that are young or high-risk. The data showed that BTZ maintenance is effective and safe in...

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

Posted by Medivizor on Jan 23, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of clofarabine (Clolar)-fludarabine (Fludara)-busulfan (Busulfex) as a conditioning regime in hematopoietic stem cell transplant (HSCT) for children with acute leukemia. This study concluded that this combination is safe and effective in these patients. Some...

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

Posted by Medivizor on Jan 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study reviewed the long-term use of sodium-glucose co-transporter 2 inhibitors (SGLT-2i) on the risk of mortality and hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) and heart failure (HF). The authors concluded that long-term use of SGLT-2 inhibitors can help to reduce mortality risk and HHF in...

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Posted by Medivizor on Jan 19, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of docetaxel (Taxotere) given every 2 weeks plus androgen-deprivation therapy (ADT) in patients with metastatic castration-naïve prostate cancer (mCNPC). The data showed that docetaxel given every 2 weeks plus ADT was safe and effective in these patients. Some background MCNPC...

Updated NCCN guidelines for acute lymphoblastic leukemia.

Posted by Medivizor on Jan 16, 2022 in Leukemia | 0 comments

In a nutshell These guidelines aimed to update treatment options for patients with Philadelphia chromosome-positive (Ph+) and negative (Ph-) acute lymphoblastic leukemia (ALL). Some background Acute lymphoblastic leukemia (ALL) represents 75% to 80% of acute leukemia among children and so is the most common form of childhood leukemia. It represents...

Comparing tibial nerve stimulation and antimuscarinic agents for the treatment of overactive bladder syndrome.

Posted by Medivizor on Jan 16, 2022 in Overactive bladder | 0 comments

In a nutshell This study compared the effectiveness and safety of tibial nerve stimulation (TNS) versus antimuscarinic agents for the treatment of patients with overactive bladder (OAB). The study found that TNS was safer and as effective as antimuscarinic agents for the treatment of OAB. Some background Overactive bladder (OAB) occurs when the...

Do combination therapies given in fixed-doses polypills with aspirin reduce the risk of cardiovascular disease events?

Posted by Medivizor on Jan 16, 2022 in Hypertension | 0 comments

In a nutshell This study investigated whether a combination pill given in fixed doses with or without aspirin can reduce the risk of cardiovascular disease events in patients without a previous history of cardiovascular disease. The data showed that a fixed-dose combination treatment strategy with aspirin significantly reduced the risks of...

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Posted by Medivizor on Jan 16, 2022 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC). The data showed that alectinib (Alecensa) and lorlatinib (Lorbrena) were the most effective and safest first-line treatment options for these patients. Some background...

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by Medivizor on Jan 9, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities) can be found in...

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Posted by Medivizor on Jan 9, 2022 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness. Some background BRCA1 and BRCA2 gene mutations (abnormalities)...

Treatment Posts on Medivizor

Evaluating the effectiveness and safety of combining proton plus carbon-ion radiotherapy with chemotherapy given at the same time in patients with limited-stage small-cell lung cancer.

Evaluating the effectiveness and safety of radiotherapy for the treatment of patients with painless non-Hodgkin lymphoma.

How useful is bortezomib maintenance after allogeneic stem cell transplant in young or high-risk patients with multiple myeloma?

Clofarabine-fludarabine-busulfan conditioning before hematopoietic stem cell therapy in children with acute leukemia

How beneficial is sodium-glucose co-transporter 2 inhibitor treatment for patients with type 2 diabetes mellitus and heart failure?

Evaluating the effectiveness and safety of docetaxel given every 2 weeks plus androgen deprivation therapy in patients with metastatic castration-naïve prostate cancer.

Updated NCCN guidelines for acute lymphoblastic leukemia.

Comparing tibial nerve stimulation and antimuscarinic agents for the treatment of overactive bladder syndrome.

Do combination therapies given in fixed-doses polypills with aspirin reduce the risk of cardiovascular disease events?

Comparing the effectiveness and safety of first-line treatment options in patients with advanced ALK-rearranged NSCLC.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.

Categories

Recent Posts

Archives

Treatment Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email